- Home
- AGEN vs CTW Comparison
AGEN vs CTW Comparison
Compare AGEN & CTW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- CTW
- Stock Information
- Founded
- AGEN 1994
- CTW 2013
- Country
- AGEN United States
- CTW Japan
- Employees
- AGEN N/A
- CTW N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- CTW EDP Services
- Sector
- AGEN Health Care
- CTW Technology
- Exchange
- AGEN Nasdaq
- CTW Nasdaq
- Market Cap
- AGEN 142.8M
- CTW 150.4M
- IPO Year
- AGEN 2000
- CTW 2025
- Fundamental
- Price
- AGEN $4.25
- CTW $2.35
- Analyst Decision
- AGEN Buy
- CTW
- Analyst Count
- AGEN 2
- CTW 0
- Target Price
- AGEN $14.50
- CTW N/A
- AVG Volume (30 Days)
- AGEN 431.2K
- CTW 336.0K
- Earning Date
- AGEN 11-11-2025
- CTW 11-09-2025
- Dividend Yield
- AGEN N/A
- CTW N/A
- EPS Growth
- AGEN N/A
- CTW N/A
- EPS
- AGEN N/A
- CTW N/A
- Revenue
- AGEN $101,706,000.00
- CTW $76,194,020.00
- Revenue This Year
- AGEN $60.49
- CTW N/A
- Revenue Next Year
- AGEN N/A
- CTW N/A
- P/E Ratio
- AGEN N/A
- CTW $56.62
- Revenue Growth
- AGEN N/A
- CTW 8.71
- 52 Week Low
- AGEN $1.38
- CTW $1.71
- 52 Week High
- AGEN $7.34
- CTW $4.88
- Technical
- Relative Strength Index (RSI)
- AGEN 45.64
- CTW N/A
- Support Level
- AGEN $3.78
- CTW N/A
- Resistance Level
- AGEN $4.38
- CTW N/A
- Average True Range (ATR)
- AGEN 0.24
- CTW 0.00
- MACD
- AGEN 0.00
- CTW 0.00
- Stochastic Oscillator
- AGEN 47.55
- CTW 0.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About CTW CTW Cayman Class A Ordinary Shares
CTW Cayman is a web-based gaming platform, offering players an immersive digital space through flagship HTML5 platform, G123.jp. The company's primary focus is to serve game developers by providing a comprehensive platform that helps them generate revenue and reach a global audience. The platform offers a diverse selection of free-to-play games inspired by popular Japanese animations and it hosts 28 games, with 9 additional titles in pre-registration.